Bayer and Vanderbilt University Medical Center announced that they have entered a strategic five-year collaboration agreement to advance innovative therapies from target identification through Investigational New Drug (IND) application. The agreement spans across all indications currently pursued by Bayer, initially focusing on cardiovascular and kidney diseases, two therapeutic areas with significant unmet medical need. The collaboration will leverage VUMC's resource platform, including its comprehensive datasets hosted in Vanderbilt's BioVU collection of DNA and Plasma to enable data-driven insights and to accelerate discovery and development.
It will combine Bayer's expertise in drug discovery and translational sciences with VUMC's deep preclinical and clinical knowledge.
